Physician profile
Huma M Hyder
NPI 1629049903
$4,157.19
in general payments reported to CMS, 2019-2025
27 companies · $793 in 2025
The $793 reported for 2025 was more than what 78% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,285 · 2020: $669 · 2021: $365 · 2022: $479 · 2023: $234 · 2024: $332 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $751.86 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $416.84 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $372.65 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Allergan, INC. | $367.52 | 2019-2020 | |
| Lundbeck LLC | $254.28 | 2019-2025 | Rexulti |
| Alkermes, INC. | $209.73 | 2022-2025 | Aristada, Lybalvi |
| Abbvie INC. | $208.84 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.48 | 2020-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $199.45 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $181.32 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Vanda Pharmaceuticals INC. | $175.30 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $143.52 | 2020-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $96.58 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $84.91 | 2019-2020 | |
| Corium, LLC | $73.23 | 2022-2024 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $62.92 | 2019-2023 | Wellbutrin, Aplenzin |
| Merck Sharp & Dohme LLC | $62.71 | 2019-2022 | |
| Axsome Therapeutics, INC. | $49.47 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $39.73 | 2019-2024 | Trintellix |
| Shire North American Group INC | $34.71 | 2019 | |
| Almatica Pharma LLC | $28.72 | 2022 | |
| Tms Neurohealth Centers INC. | $28.23 | 2025 | Tms Neurohealth Centers INC. |
| Supernus Pharmaceuticals, INC. | $27.75 | 2025 | Qelbree |
| Vertical Pharmaceuticals, LLC | $27.54 | 2019-2020 | |
| Neuronetics, INC. | $22.09 | 2020 | |
| Tris Pharma INC | $20.74 | 2019 | |
| Eisai INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Hyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.